SCHEMBL15769449

SCHEMBL15769449

CN(C)c1cnc(Nc2cccc(C#N)c2)nc1N(C)[C@H]1CCCN2CCCC[C@H]12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.42
CDC7 O00311 1/20 0.42
MAOB P27338 1/20 0.42
GRM5 P41594 1/20 0.42
PRKDC P78527 1/20 0.40
MAP4K1 Q92918 1/20 0.40
IGF1R P08069 1/20 0.39
SMG1 Q96Q15 1/20 0.36
SLC2A1 P11166 1/20 0.36
CDK4 P11802 2/20 0.36
CDK2 P24941 2/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK1 P06493 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769702 0.90 JAK3 (0.42) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15770162 0.90 SYK (0.42) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15769281 0.90 SYK (0.51) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15769385 0.88 JAK3 (0.47) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15770252 0.88 ABCG2 (0.43) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15769866 0.86 CDK1 (0.36) SYKGRM5MAP4K1CDK4CDK2
SCHEMBL15770094 0.85 JAK3 (0.38) GRM5PRKDCCDK4CDK2CDK1
SCHEMBL15769441 0.83 JAK3 (0.50) SYKCDC7MAOBGRM5PRKDC
SCHEMBL15769451 0.81 SYK (0.44) SYKCDC7MAOBGRM5MAP4K1
SCHEMBL15769976 0.78 CDK1 (0.39) SYKMAP4K1IGF1RCDK4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB SYK 612/4885CDC7 322/4885MAOB 2123/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB SYK 612/4885CDC7 322/4885MAOB 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.